Nephroprotective effects of subcapsular transplantation of metanephric mesenchymal cells on gentamicin-induced acute tubular necrosis in rats.

World Journal of Pediatrics : WJP
Lin LiuShuang-Hong Mo

Abstract

The subcapsular transplantation of metanephric mesenchymal cells (MMCs) may be a new therapeutic approach for the treatment of acute tubular necrosis (ATN). To investigate this hypothesis and provide evidence for its possible use in the clinic, we evaluated the nephroprotective effects of transplanting MMCs into the renal subcaspsule of rats with ATN induced by gentamicin. MMCs were expanded in culture. After gentamicin-induced ATN was established, fluorescently-labeled cells were transplanted and traced in kidney tissues by fluorescence microscopy. Serum creatinine (Cr), urea nitrogen (BUN), and N-acetyl-b-D-glucosaminidase (NAG) levels were determined at different time points. Kidney pathology was studied by hematoxylin-eosin staining. Apoptosis was examined by the TUNEL assay. In the MMCs-treated group, the mortality rate decreased; BUN, Cr, and NAG levels peaked at 8 days, and were significantly lower than those in the other groups at 11 and 14 days. RIMM-18 cells locally recruited through precise tropism to sites of injury had the ability to migrate into the tubuli from the renal subcapsule. Damage to the cell-treated kidneys was reduced. The pathologic lesion scores of tubular damage reached the highest values at 8 days i...Continue Reading

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S B MillerM R Hammerman
May 30, 1996·The New England Journal of Medicine·R ThadhaniJ V Bonventre
Jun 29, 2000·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·M R Hammerman
Apr 5, 2001·Nature·D OrlicP Anversa
Oct 10, 2001·The Journal of Pathology·R PoulsomN A Wright
Feb 19, 2002·Kidney International·Qais Al-Awqati, Juan A Oliver
Sep 10, 2002·American Journal of Physiology. Renal Physiology·Juan A OliverQais Al-Awqati
Apr 23, 2003·Journal of the American Society of Nephrology : JASN·Fangming LinPeter Igarashi
May 20, 2003·Kidney International·Zoia B LevashovaAlan O Perantoni
May 23, 2003·Journal of the American Society of Nephrology : JASN·Joseph V Bonventre
Jun 26, 2003·The Journal of Clinical Investigation·Sujata KaleLloyd G Cantley
Sep 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Hiroshi KonoYoshiro Matsumoto
Oct 9, 2003·Kidney International·A Meguid El-Nahas
Nov 26, 2003·Journal of the American Society of Nephrology : JASN·Akito MaeshimaYoshihisa Nojima
May 26, 2004·Transplant Immunology·Benjamin Dekel, Yair Reisner
Jun 24, 2004·Journal of the American Society of Nephrology : JASN·Marina MorigiGiuseppe Remuzzi
Jul 3, 2004·The Journal of Clinical Investigation·Robert W SchrierAmit Mitra
Jul 12, 2005·The Journal of Clinical Investigation·Fangming LinPeter Igarashi
Oct 14, 2005·Kidney International·Hermann HallerDanilo Fliser
Feb 21, 2006·Current Opinion in Pharmacology·Daniel PatschanMichael S Goligorsky
Mar 22, 2006·Pediatric Research·Fangming Lin
Mar 28, 2006·Journal of the American Society of Nephrology : JASN·Gianpaolo ZerbiniGiuseppe Bianchi
Apr 28, 2006·Archivum Immunologiae Et Therapiae Experimentalis·Ewa Watorek, Marian Klinger
Dec 21, 2010·Néphrologie & thérapeutique·Martial MoonenXavier Warling

❮ Previous
Next ❯

Citations

Mar 6, 2013·PloS One·Linong JiUNKNOWN Evidence-Based Medical Research of Xiaoke Pill Study Group
Jul 20, 2018·Journal of Cellular and Molecular Medicine·Jiping SunAiping Yin
Jan 21, 2017·Experimental and Therapeutic Medicine·Meng JiWeijun Guan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
David VansthertemGérard Toubeau
Néphrologie & thérapeutique
Benjamin D Humphreys, Joseph V Bonventre
© 2021 Meta ULC. All rights reserved